Regulacje i polityka gospodarcza · 20/12/1995

Opportunity For Licensing: Sequence Modification of Oligonucleotide Primers to Manipulate Non-Templated Nucleotide Addition

The National Institutes of Health (NIH) seeks licensees to commercialize a method to manipulate non-templated nucleotide addition to ensure that all amplified DNA products of polymerase chain reaction (PCR) are either specifically modified or unmodified. This technology was developed by Dr. Jeffrey R. Smith and Dr. John Carpten of the National Center for Human Genome Research and Dr. Michael Brownstein of the National Institute of Mental Health. The invention embodied in U.S. Provisional Patent Application 60/ 005, 761 filed October 20, 1995, entitled ``Sequence Modification of Oligonucleotide Primers to Manipulate Non-Templated Nucleotide Addition,'' is owned by an agency of the U.S.Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 or pursuant to 42 U.S.C. 241 to achieve expeditious commercialization of results of federally-funded research and development.